NOVOCURE LTD (NVCR)

JE00BYSS4X48 - Common Stock

28.91  -0.1 (-0.34%)

After market: 28.92 +0.01 (+0.03%)

Fundamental Rating

2

Overall NVCR gets a fundamental rating of 2 out of 10. We evaluated NVCR against 187 industry peers in the Health Care Equipment & Supplies industry. NVCR has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, NVCR is valued expensive at the moment.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year NVCR has reported negative net income.
NVCR had a negative operating cash flow in the past year.
In the past 5 years NVCR reported 4 times negative net income.
Of the past 5 years NVCR 4 years had a positive operating cash flow.

1.2 Ratios

NVCR has a Return On Assets of -12.26%. This is comparable to the rest of the industry: NVCR outperforms 56.99% of its industry peers.
With a Return On Equity value of -41.52%, NVCR perfoms like the industry average, outperforming 53.23% of the companies in the same industry.
Industry RankSector Rank
ROA -12.26%
ROE -41.52%
ROIC N/A
ROA(3y)-10.32%
ROA(5y)-6.11%
ROE(3y)-30.77%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NVCR's Gross Margin of 76.42% is amongst the best of the industry. NVCR outperforms 88.17% of its industry peers.
NVCR's Gross Margin has improved in the last couple of years.
NVCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.57%
GM growth 5Y2.01%

More info and screens

1

2. Health

2.1 Basic Checks

NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NVCR has been increased compared to 1 year ago.
NVCR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NVCR has a worse debt to assets ratio.

2.2 Solvency

NVCR has an Altman-Z score of 1.34. This is a bad value and indicates that NVCR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NVCR (1.34) is comparable to the rest of the industry.
NVCR has a Debt/Equity ratio of 1.81. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.81, NVCR is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.81
Debt/FCF N/A
Altman-Z 1.34
ROIC/WACCN/A
WACC8.34%

2.3 Liquidity

A Current Ratio of 1.49 indicates that NVCR should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.49, NVCR is doing worse than 77.42% of the companies in the same industry.
A Quick Ratio of 1.44 indicates that NVCR should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.44, NVCR is doing worse than 62.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.49
Quick Ratio 1.44

More info and screens

5

3. Growth

3.1 Past

NVCR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.73%, which is quite impressive.
The Revenue has grown by 14.63% in the past year. This is quite good.
Measured over the past years, NVCR shows a quite strong growth in Revenue. The Revenue has been growing by 15.47% on average per year.
EPS 1Y (TTM)24.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.13%
Revenue 1Y (TTM)14.63%
Revenue growth 3Y1%
Revenue growth 5Y15.47%
Sales Q2Q%21.81%

3.2 Future

NVCR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.34% yearly.
Based on estimates for the next years, NVCR will show a quite strong growth in Revenue. The Revenue will grow by 18.98% on average per year.
EPS Next Y32.07%
EPS Next 2Y9.32%
EPS Next 3Y7.18%
EPS Next 5Y8.34%
Revenue Next Year17.36%
Revenue Next 2Y11.21%
Revenue Next 3Y11.16%
Revenue Next 5Y18.98%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NVCR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.32%
EPS Next 3Y7.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVCR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVOCURE LTD

NASDAQ:NVCR (1/8/2025, 8:19:45 PM)

After market: 28.92 +0.01 (+0.03%)

28.91

-0.1 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)N/A N/A
Inst Owners86.68%
Inst Owner Change0%
Ins Owners1.89%
Ins Owner Change0.1%
Market Cap3.13B
Analysts80
Price Target35.7 (23.49%)
Short Float %5.3%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.93%
Min EPS beat(2)17.78%
Max EPS beat(2)26.08%
EPS beat(4)4
Avg EPS beat(4)18.94%
Min EPS beat(4)15.39%
Max EPS beat(4)26.08%
EPS beat(8)5
Avg EPS beat(8)2.11%
EPS beat(12)7
Avg EPS beat(12)-7.99%
EPS beat(16)7
Avg EPS beat(16)-136.07%
Revenue beat(2)2
Avg Revenue beat(2)7.08%
Min Revenue beat(2)5.63%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)4.36%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)8.53%
Revenue beat(8)3
Avg Revenue beat(8)0.76%
Revenue beat(12)5
Avg Revenue beat(12)0.25%
Revenue beat(16)5
Avg Revenue beat(16)-1.08%
PT rev (1m)31.02%
PT rev (3m)28.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.03%
EPS NY rev (1m)-0.48%
EPS NY rev (3m)3.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.41
P/FCF N/A
P/OCF N/A
P/B 8.67
P/tB 8.67
EV/EBITDA N/A
EPS(TTM)-1.4
EYN/A
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS5.34
BVpS3.33
TBVpS3.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.26%
ROE -41.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.42%
FCFM N/A
ROA(3y)-10.32%
ROA(5y)-6.11%
ROE(3y)-30.77%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.57%
GM growth 5Y2.01%
F-Score5
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 1.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 375.45%
Cap/Sales 7.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.49
Quick Ratio 1.44
Altman-Z 1.34
F-Score5
WACC8.34%
ROIC/WACCN/A
Cap/Depr(3y)227.98%
Cap/Depr(5y)194.31%
Cap/Sales(3y)4.6%
Cap/Sales(5y)3.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.13%
EPS Next Y32.07%
EPS Next 2Y9.32%
EPS Next 3Y7.18%
EPS Next 5Y8.34%
Revenue 1Y (TTM)14.63%
Revenue growth 3Y1%
Revenue growth 5Y15.47%
Sales Q2Q%21.81%
Revenue Next Year17.36%
Revenue Next 2Y11.21%
Revenue Next 3Y11.16%
Revenue Next 5Y18.98%
EBIT growth 1Y29.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year67.36%
EBIT Next 3Y21.87%
EBIT Next 5Y25.4%
FCF growth 1Y-496.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-176.62%
OCF growth 3YN/A
OCF growth 5YN/A